After repeated exposure to factor VIII or IX replacement, about 30% of patients with severe hemophilia A and 3% with hemophilia B develop factor VIII orfactor IXisoantibodies (alloantibodies) that inhibit the coagulant activity of any additional factor VIII or factor IX infused.